Identification of Medicinal Products (IDMP): What is IDMP and Why Should I Care? – June 13, 2019

FDA Orphan Drugs Program and Financial Incentives for CDER Medical Products- June 10, 2019

FDA Expert Panel on Testosterone Replacement Therapy for Men

Medical Device Quality Management System Regulation Risk Management

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Identification of Medicinal Products: Path to Global Implementation

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

Public Meeting: Reauthorization of the Biosimilar User Fee Act

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Framework for FDA’s Real-World Evidence Program – Mar 15, 2019

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

Medical Device Quality Management System Regulation Design and Development

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

eCTD Submissions of Promotional Labeling and Advertising Materials

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Celebrates 120 Years

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy